U.S. Invests $15.97M in Virginia's Pharmaceutical Manufacturing Hub

Alliance for Building Better Medicine, the coalition leading Virginia's Advanced Pharmaceutical Manufacturing (APM) Tech Hub, announced a $15.97 million investment from the U.S. Economic Development Administration (EDA) to launch the End-to-End (E2E) Commercialization Project. The initiative will help establish a domestic commercialization pathway connecting innovation, manufacturing, and patients.

Led by Civica, Inc. (Civica Rx) and supported by Phlow Corp. and Occam Systems, the End-to-End Commercialization Project marks the latest milestone for the Alliance for Building Better Medicine. The Alliance includes 55 partners spanning industry, academia, workforce development, government, nonprofit organizations, and economic development, all working to strengthen America's pharmaceutical manufacturing ecosystem and expand domestic manufacturing capacity.

The project will focus on four essential sterile injectable medicines used every day in emergency, anesthesia, and critical care settings: ketamine, midazolam, norepinephrine, and succinylcholine. The partners will connect domestically sourced key starting materials, active pharmaceutical ingredients, finished dose formulations, FDA approval, and commercial manufacturing through an integrated pathway designed to expand domestic medicine production in the United States.

"Virginia is an emerging leader in advanced pharmaceutical manufacturing, and we are committed to uniting industry, researchers, educators, workforce partners, and public leaders around a shared goal: ensuring medicines are reliably developed and manufactured in the United States," said Governor Abigail Spanberger. "This transformational investment from the EDA reflects a confidence in Virginia's future that will help us create job opportunities for Virginians, encourage innovation, and strengthen our nation's pharmaceutical manufacturing ecosystem."